KIM YONG IL,KWON YOENG JIN,PARK CALEB HYUNGMIN,LEE SEUNG YEOP,PARK JAE HYUN,WOO JONG SOO
申请号：
IN1738DEN2015
公开号：
IN1738DEN2015A
申请日:
2015.03.03
申请国别(地区):
IN
年份:
2015
代理人:
摘要：
Disclosed are a pharmaceutical composite capsule formulation comprising 1) an independent irbesartan unit comprising irbesartan or a pharmaceutically acceptable salt thereof； and 2) an independent HMG CoA reductase inhibitor unit comprising an HMG CoA reductase inhibitor or a pharmaceutically acceptable salt thereof and an alkaline additive wherein said independent units are separated from each other within a capsule and a method for preparing the same. Designed to prevent an interaction between irbesartan and the HMG CoA reductase inhibitor the pharmaceutical composite capsule formulation is improved in stability and dissolution rate and thus shows great bioavailability. In addition the formulation is expected to guarantee high drug compliance owing to its small size and therefore can be applied to the treatment of hypertension and hypercholesterolemia.
